These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
Nevada
|
45-2859440
|
|
|
(State or other jurisdiction of
incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
| Large accelerated filer | o | Accelerated filer | o |
| Non-accelerated filer | o | Smaller reporting company | þ |
| (Do not check if a smaller reporting company) | |||
|
|
Page
|
|
|
PART I.
|
FINANCIAL INFORMATION
|
|
|
ITEM 1.
|
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
|
4
|
|
ITEM 2.
|
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
|
20
|
|
ITEM 3.
|
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
|
24
|
|
ITEM 4.
|
CONTROLS AND PROCEDURES
|
24
|
|
PART II.
|
OTHER INFORMATION
|
|
|
ITEM 1.
|
LEGAL PROCEEDINGS
|
25
|
|
ITEM 1A.
|
RISK FACTORS
|
25
|
|
ITEM 2.
|
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
|
25
|
|
ITEM 3.
|
DEFAULTS UPON SENIOR SECURITIES
|
25
|
|
ITEM 4.
|
MINE SAFETY DISCLOSURES
|
25
|
|
ITEM 5.
|
OTHER INFORMATION
|
25
|
|
ITEM 6.
|
EXHIBITS
|
26
|
|
Condensed Consolidated Balance Sheets (unaudited)
|
6
|
|
Condensed Consolidated Statements of Operations (unaudited)
|
7
|
|
|
|
|
Condensed Consolidated Statements of Comprehensive Loss (unaudited)
|
8
|
|
Condensed Consolidated Statements of Cash Flows (unaudited)
|
9
|
|
Notes to the Condensed Consolidated Financial Statements (unaudited)
|
10
|
|
March 31,
|
December 31,
|
|||||||
|
2014
|
2013
|
|||||||
|
ASSETS
|
||||||||
|
Current assets
|
||||||||
|
Cash
|
$ | 539,796 | $ | 891,592 | ||||
|
Accounts receivable, less allowance for doubtful accounts of $17,737 and $10,718 respectively
|
21,955 | 2,897 | ||||||
|
Prepaid expenses and other current assets
|
66,355 | 59,486 | ||||||
|
Total current assets
|
628,106 | 953,975 | ||||||
|
Property and equipment - at cost, less accumulated
|
||||||||
|
depreciation and amortization
|
3,917 | 4,259 | ||||||
|
Investment in Equidam Holding B.V.
|
1,430 | 1,432 | ||||||
|
Total assets
|
$ | 633,453 | $ | 959,666 | ||||
|
LIABILITIES AND STOCKHOLDERS' DEFICIT
|
||||||||
|
Current liabilities
|
||||||||
|
Accounts payable
|
$ | 171,292 | $ | 138,495 | ||||
|
Accrued expenses and other current liabilities
|
165,332 | 256,928 | ||||||
|
Deferred government grants
|
2,752 | 11,017 | ||||||
|
Current maturities of notes payable
|
41,603 | 41,657 | ||||||
|
Total current liabilities
|
380,979 | 448,097 | ||||||
|
Notes payable, less current maturities
|
237,662 | 237,973 | ||||||
|
Derivative liability - warrants
|
325,610 | 303,662 | ||||||
|
Total liabilities
|
944,251 | 989,732 | ||||||
|
Commitments
|
||||||||
|
Stockholders' deficit
|
||||||||
|
Preferred stock
|
||||||||
|
Authorized: $0.001 par value, 10,000,000 shares authorized
|
- | - | ||||||
|
Issued and outstanding: nil preferred shares
|
||||||||
|
Common stock
|
||||||||
|
Authorized: $0.001 par value, 290,000,000 shares authorized
|
||||||||
|
Issued and outstanding: 34,642,720 and 34,268,736 respectively
|
34,642 | 34,268 | ||||||
|
Additional paid-in capital
|
2,182,708 | 2,041,052 | ||||||
|
Accumulated other comprehensive loss
|
(44,422 | ) | (44,029 | ) | ||||
|
Accumulated deficit
|
(2,413,630 | ) | (2,001,760 | ) | ||||
|
Total Symbid Corp. stockholders' equity (deficit)
|
(240,702 | ) | 29,531 | |||||
|
Noncontrolling interests
|
(70,096 | ) | (59,597 | ) | ||||
|
Total stockholders' deficit
|
(310,798 | ) | (30,066 | ) | ||||
|
Total liabilities and stockholders' deficit
|
$ | 633,453 | $ | 959,666 | ||||
|
Three months ended
|
||||||||
|
March 31,
|
||||||||
|
2014
|
2013
|
|||||||
|
Revenues
|
||||||||
|
Crowd funding
|
$ | 78,055 | $ | 17,858 | ||||
|
Other
|
8,050 | 1,664 | ||||||
|
Total revenues
|
86,105 | 19,522 | ||||||
|
Operating expenses
|
||||||||
|
Selling general and administrative
|
274,015 | 75,196 | ||||||
|
Professional fees
|
204,713 | 13,713 | ||||||
|
Research and development costs
|
45,975 | - | ||||||
|
Depreciation and amortization
|
334 | 320 | ||||||
|
Total operating expenses
|
525,037 | 89,229 | ||||||
|
Operating loss
|
(438,932 | ) | (69,707 | ) | ||||
|
Other income (expense)
|
||||||||
|
Fair value adjustment derivative liability - warrants
|
15,264 | - | ||||||
|
Interest expense
|
(5,810 | ) | (4,940 | ) | ||||
|
Government subsidy
|
8,221 | 7,869 | ||||||
|
Equity in losses of Gambitious B.V.
|
- | (22,489 | ) | |||||
|
Other income and expense
|
(1,631 | ) | - | |||||
|
Total other income (expense)
|
16,044 | (19,560 | ) | |||||
|
Net loss
|
(422,888 | ) | (89,267 | ) | ||||
|
Net loss attributable to noncontrolling interests
|
(11,018 | ) | (15,815 | ) | ||||
|
Net loss attributable to Symbid Corp. stockholders
|
$ | (411,870 | ) | $ | (73,452 | ) | ||
|
Basic and diluted net loss per common share
|
$ | (0.02 | ) | $ | (0.00 | ) | ||
|
Weighted average number of shares outstanding
|
||||||||
|
Basic and diluted
|
26,498,864 | 21,103,810 | ||||||
|
Three months ended
|
||||||||
|
March 31,
|
||||||||
|
2014
|
2013
|
|||||||
|
Net loss
|
$ | (422,888 | ) | $ | (89,267 | ) | ||
|
Other comprehensive loss:
|
||||||||
|
Foreign currency translation adjustments
|
(393 | ) | 6,955 | |||||
|
Comprehensive loss
|
(423,281 | ) | (82,312 | ) | ||||
|
Net loss attributable to noncontrolling interests
|
(11,018 | ) | (15,815 | ) | ||||
|
Foreign currency translation income (loss) attributable to noncontrolling interests
|
519 | (171 | ) | |||||
|
Comprehensive loss attributable to noncontrolling interests
|
(10,499 | ) | (15,986 | ) | ||||
|
Comprehensive loss attributable to Symbid Corp. stockholders
|
$ | (412,782 | ) | $ | (66,326 | ) | ||
|
Three months ended March 31,
|
||||||||
|
2014
|
2013
|
|||||||
|
Cash flows from operating activities
|
||||||||
|
Net loss
|
$ | (422,888 | ) | $ | (89,267 | ) | ||
|
Adjustments to reconcile net loss to net cash
|
||||||||
|
used in operating activities
|
||||||||
|
Depreciation and amortization
|
334 | 320 | ||||||
|
Losses recorded from investment in Gambitious B.V.
|
- | 22,489 | ||||||
|
Fair value adjustment derivative liability - warrants
|
(15,264 | ) | - | |||||
|
Deferred government grants
|
(8,221 | ) | (7,869 | ) | ||||
|
Provision for doubtful accounts
|
7,007 | - | ||||||
|
Changes in assets and liabilities
|
||||||||
|
Accounts receivable
|
(26,002 | ) | (1,224 | ) | ||||
|
Prepaid expenses and other current assets
|
(6,921 | ) | 3,284 | |||||
|
Accounts payable
|
32,859 | 4,853 | ||||||
|
Accrued expenses and other current liabilities
|
(90,925 | ) | (20,716 | ) | ||||
|
Net cash used in operating activities
|
(530,021 | ) | (88,130 | ) | ||||
|
Cash flows from financing activities
|
||||||||
|
Proceeds from the issuance of common stock and warrants, net of issuance costs
|
$ | 179,242 | $ | - | ||||
|
Proceeds from capital contribution
|
- | 302,206 | ||||||
|
Net cash provided by financing activities
|
179,242 | 302,206 | ||||||
|
Effect of exchange rate changes on cash
|
(1,017 | ) | 2,150 | |||||
|
Net (decrease) / increase in cash
|
(351,796 | ) | 216,226 | |||||
|
Cash and cash equivalents, beginning of year
|
891,592 | 7,732 | ||||||
|
Cash and cash equivalents, end of year
|
$ | 539,796 | $ | 223,958 | ||||
|
Supplemental cash flow disclosures
|
||||||||
|
Interest paid
|
$ | 3,807 | $ | 2,229 | ||||
|
Non-cash financing activities
|
||||||||
|
Conversion of notes payable into common stock
|
$ | - | $ | 85,951 | ||||
|
March 31,
2014
|
December 31,
2013
|
|||||||
|
Current assets
|
$
|
118,609
|
$
|
53,414
|
||||
|
Current liabilities
|
$
|
188,706
|
$
|
113,137
|
||||
|
March 31,
2014
|
December 31,
2013
|
|||||||
|
Working capital facility
|
$
|
187,195
|
$
|
187,371
|
||||
|
Subordinated loan – related party
|
92,070
|
92,259
|
||||||
|
Total notes payable
|
279,265
|
279,630
|
||||||
|
Less - Current Maturities
|
(41,603
|
)
|
(41,657
|
)
|
||||
|
Notes payable, less current maturities
|
$
|
237,662
|
$
|
237,973
|
||||
|
1.
|
Long term loan for approximately $240,000, bears interest of approximately 6.4% and is payable quarterly with principal. The loan decreases on a quarterly basis by approximately $10,000, starting on September 30, 2012. As of March 31, 2014 the loan balance was $187,195.
|
|
2.
|
A line of credit of approximately $80,000 with a floating interest rate of approximately 4.5% at December 31, 2013. The balance on the credit facility at March 31, 2014 was $0.
|
|
1.
|
Assets of the Company including receivables and intellectual property developed by the Company.
|
|
2.
|
Guarantee by principal members of management up to approximately $60,000.
|
|
3.
|
Guarantee by the Netherlands government for the remaining balance in a hypothetical liquidation up to approximately $264,000.
|
| THE TWELVE MONTHS ENDING MARCH 31, 2014 | ||||
|
2014
|
$
|
41,603
|
||
|
2015
|
133,672
|
|||
|
2016
|
41,603
|
|||
|
2017
|
41,603
|
|||
|
2018
|
20,784
|
|||
|
$
|
279,265
|
|||
|
Gross Proceeds from the PPO
|
$
|
1,736,355
|
||
|
Issuance costs
|
(68,000
|
)
|
||
|
Proceeds allocated to warranty liability
|
(343,105
|
)
|
||
|
Proceeds allocated to common stock
|
$
|
1,325,250
|
|
March 31,
2014
|
March 31,
2013
|
|||||||
|
Symbid Coop - 100%
|
$
|
10,412
|
$
|
7,494
|
||||
|
Gambitious Coop - 37%
|
606
|
8,321
|
||||||
|
Total net loss attributable to noncontrolling interests
|
$
|
11,018
|
$
|
15,815
|
||||
|
|
March 31,
|
December 31,
|
||||||
|
|
2014
|
2013
|
||||||
|
Investor Warrants
|
||||||||
|
Implied starting stock price
|
$
|
0.42
|
$
|
0.42
|
||||
|
Volatility
|
55
|
%
|
55
|
%
|
||||
|
Drift
|
0.75
|
%
|
0.75
|
%
|
||||
|
Exercise price
|
$
|
0.75
|
$
|
0.75
|
||||
|
Minimum exercise price
|
$
|
0.01
|
$
|
0.01
|
||||
|
Warrant shares
|
3,472,720
|
3,098,736
|
||||||
|
Event date
|
September 30, 2014
|
September 30, 2014
|
||||||
|
Maturity
|
December 5, 2016
|
December 5, 2016
|
||||||
|
Shares outstanding
|
34,642,720
|
34,268,736
|
||||||
|
|
March 31,
|
December 31,
|
||||||
|
|
2014
|
|
2013
|
|||||
|
Broker Warrants
|
||||||||
|
Implied starting stock price
|
$
|
0.39
|
$
|
0.42
|
||||
|
Volatility
|
55
|
%
|
55
|
%
|
||||
|
Drift
|
0.75
|
%
|
0.75
|
%
|
||||
|
Exercise price
|
$
|
0.50
|
$
|
0.50
|
||||
|
Minimum exercise price
|
$
|
0.01
|
$
|
0.01
|
||||
|
Warrant shares
|
93,000
|
77,500
|
||||||
|
Event date
|
September 30, 2014
|
September 30, 2014
|
||||||
|
Maturity
|
December 5, 2016
|
December 5, 2016
|
||||||
|
Shares outstanding
|
34,642,720
|
34,268,736
|
||||||
|
December 31, 2013 Fair Value of Warrant Liability
|
Fair Value of Warrants Issued in the three months ended March 31, 2014
|
Realized Gain on
change in fair value of Warrant Liabilities |
March 31, 2014 Fair Value of Warrant Liability
|
|||||||||||||
|
Investor Warrants
|
294,298 | 35,358 | (14,874 | ) | 314,782 | |||||||||||
|
Broker Warrants
|
9,364 | 1,854 | (390 | ) | 10,828 | |||||||||||
|
Total
|
303,662 | 37,212 | (15,264 | ) | 325,610 | |||||||||||
|
March 31,
2014
|
December 31,
2013
|
|||||||
|
Advisory and professional costs
|
$
|
71,387
|
$
|
172,051
|
||||
|
Travel and hotel costs
|
-
|
15,272
|
||||||
|
Development costs
|
10,577
|
10,063
|
||||||
|
Management fee
|
22,784
|
-
|
||||||
|
Interest
|
9,361
|
8,451
|
||||||
|
Wage tax' return
|
21,631
|
15,177
|
||||||
|
Holiday pay allowance/Net salary
|
6,080
|
17,648
|
||||||
|
Other current liabilities
|
23,512
|
18,266
|
||||||
|
$
|
165,332
|
$
|
256,928
|
|||||
|
●
|
Consolidated revenue totaled $86,105, an increase of over 100% compared to the prior year period.
|
|
●
|
Approximately $78,055 or 90% of our revenue was attributable to core crowdfunding activities consistent with the prior year period.
|
|
●
|
Selling, general and administrative expenses and professional fees totaled $274,015 and $204,713, respectively, an increase of over 100% compared to the prior year period.
|
|
●
|
Net cash used by operating activities totaled $530,021 for the quarter ending March 31, 2014 and cash on hand at March 31, 2014 was $539,796.
|
|
Three months ended
|
||||||||
|
March 31,
|
||||||||
|
2014
|
2013
|
|||||||
|
Revenues
|
||||||||
|
Crowd funding
|
$ | 78,055 | $ | 17,858 | ||||
|
Other
|
8,050 | 1,664 | ||||||
|
Total revenues
|
86,105 | 19,522 | ||||||
|
Operating expenses
|
||||||||
|
Selling general and administrative
|
274,015 | 75,196 | ||||||
|
Professional fees
|
204,713 | 13,713 | ||||||
|
Research and development costs
|
45,975 | - | ||||||
|
Depreciation and amortization
|
334 | 320 | ||||||
|
Total operating expenses
|
525,037 | 89,229 | ||||||
|
Operating loss
|
(438,932 | ) | (69,707 | ) | ||||
|
Other income (expense)
|
||||||||
|
Fair value adjustment derivative liability - warrants
|
15,264 | - | ||||||
|
Interest expense
|
(5,810 | ) | (4,940 | ) | ||||
|
Government subsidy
|
8,221 | 7,869 | ||||||
|
Equity in losses of Gambitious B.V.
|
- | (22,489 | ) | |||||
|
Other income and expense
|
(1,631 | ) | ||||||
|
Total other income (expense)
|
16,044 | (19,560 | ) | |||||
|
Net loss
|
(422,888 | ) | (89,267 | ) | ||||
|
Net loss attributable to noncontrolling interests
|
(11,018 | ) | (15,815 | ) | ||||
|
Net loss attributable to Symbid Corp. stockholders
|
$ | (411,870 | ) | $ | (73,452 | ) | ||
|
Basic and diluted net loss per common stock
|
$ | (0.02 | ) | $ | (0.00 | ) | ||
|
Weighted average number of shares outstanding
|
||||||||
|
Basic and diluted
|
26,498,864 | 21,103,810 | ||||||
|
Exhibit
Number
|
Description of Exhibit
|
Filing
|
||
|
31.1
|
Certification of Principal Executive Officer and Pursuant to Rule 13a-14
|
Filed herewith.
|
||
|
31.2
|
Certification of Principal Financial Officer Pursuant to Rule 13a-14
|
Filed herewith.
|
||
|
32.1*
|
CEO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act
|
Filed herewith.
|
||
|
32.2*
|
CFO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act
|
Filed herewith.
|
||
|
101.INS**
|
XBRL Instance Document
|
Filed herewith.
|
||
|
101.SCH**
|
XBRL Taxonomy Extension Schema Document
|
Filed herewith.
|
||
|
101.CAL**
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
Filed herewith.
|
||
|
101.LAB**
|
XBRL Taxonomy Extension Labels Linkbase Document
|
Filed herewith.
|
||
|
101.PRE**
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
Filed herewith.
|
||
|
101.DEF**
|
XBRL Taxonomy Extension Definition Linkbase Document
|
Filed herewith.
|
|
*
|
This certification is being furnished and shall not be deemed “filed” with the SEC for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates it by reference
|
|
**
|
XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act is deemed not filed for purposes of Section 18 of the Exchange Act and otherwise is not subject to liability under these sections.
|
|
SYMBID CORP.
|
|||
|
Dated: May __, 2014
|
By:
|
/s/ Korstiaan Sandvliet | |
|
By: Korstiaan Sandvliet
|
|||
|
Its: President and Chief Executive Officer
|
|||
| /s/ Philip Cooke | |||
|
By: Philip Cooke
|
|||
|
Its: Chief Financial Officer
|
|||
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|